1. P10.18.A Replication of previous GWAS identifies TERT and near EGFR SNVs as risk factors in EPIC glioma patients: a nested case-control study. (5th September 2022) Authors: Wu, W; Dahlin, A; Andersson, U; Wibom, C; Jonsson, S; Melin, B Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin. Issue 2 (17th October 2012) Authors: Stocker, S L; Morrissey, K M; Yee, S W; Castro, R A; Xu, L; Dahlin, A; Ramirez, A H; Roden, D M; Wilke, R A; McCarty, C A; Davis, R L; Brett, C M; Giacomini, K M Journal: Clinical pharmacology & therapeutics Issue: Volume 93:Issue 2(2013) Page Start: 186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗